Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-03084014 in Advanced Triple-Negative Breast Cancer
NCT02299635Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Feb 2015
- Primary completion
- Jan 2016
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of nirogacestat in triple-negative breast cancer (TNBC), sponsored by Pfizer. Started Feb 2015; status: terminated.
02
Drugs
nirogacestat
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02299635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02299635.